• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    P

    Providence Health & Services

    EST. 1859
    942论文总数
    2.5万引用总数

    Providence Health & Services (since 2016: Providence St. Joseph Health) is a not-for-profit, Catholic health care system operating multiple hospitals across seven states, with headquarters in Renton, Washington. The health system includes 51 hospitals, more than 800 non-acute facilities and numerous other health, supportive housing and educational services on the west coast of the United States (Alaska, Washington, Oregon, and California) as well as Montana, New Mexico, and Texas. Providence Health & Services was founded by the Sisters of Providence in 1859.

    论文量&引用量时间轴

    机构学者

    排序
    Michelle A Williams
    Michelle A Williams
    Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Harvard University;Department of Public Policy, John F. Kennedy School of Government, Harvard University
    论文:44引用:0H-index:0
    Chunfang Qiu
    Chunfang Qiu
    Department of Neurosurgery, University of Maryland School of Medicine
    论文:24引用:0H-index:0
    Oren K. Fix
    Oren K. Fix
    Division of Gastroenterology, University of California
    论文:20引用:0H-index:0
    David Luthy
    David Luthy
    Obstetrix Medical Group (DAL), Seattle, Washington, USA
    论文:19引用:0H-index:0
    Gary Grunkemeier
    Gary Grunkemeier
    Medical Data Research Center, Providence Health and Services
    论文:16引用:0H-index:0
    David Bar-Or
    David Bar-Or
    Swedish Medical Center
    论文:13引用:0H-index:0
    Robert Resta
    Robert Resta
    Swedish Medical Center Seattle
    论文:12引用:0H-index:0
    John Henson
    John Henson
    Swedish Medical Center Seattle
    论文:12引用:0H-index:0
    Robert G. Resta
    Robert G. Resta
    Swedish Medical Center
    论文:12引用:0H-index:0

    论文(942)

    年份
    起
    –
    止
    排序
    1Large Language Models for Detecting Colorectal Polyps in Endoscopic Images.
    Luca Carlini, Davide Massimi,Yuichi Mori,Giulio Antonelli, Tommy Rizkala,Marco Spadaccini, Chiara Lena,Sravanthi Parasa,Raf Bisschops,Daniel von Renteln, Susanne O'Reilly,Prateek Sharma,
    2026Gut(2026)引用:4
    引用
    AI阅读
    加入学术空间
    2Alnuctamab, a Bivalent B-cell Maturation Antigen-Targeting T Cell Engager for Patients with Relapsed or Refractory Multiple Myeloma: Results from a Phase 1, First-in-human Study
    Noffar Bar,Thomas Martin,Craig C. Hofmeister,Maria-Victoria Mateos,Markus Hansson,Laura Paris,Swathi Namburi,Paz Ribas,Armando Santoro,Paula Rodriguez-Otero,Maria Creignou, Jinjie Chen,

    B-cell maturation antigen (BCMA)-targeting therapies provide a new approach to treating multiple myeloma (MM). Alnuctamab (ALNUC) is a 2 + 1 immunoglobulin G1-based bispecific antibody binding BCMA and CD3ε receptors on myeloma and T cells, respectively. CC-93269-MM-001 is a first-in-human, phase 1 dose escalation/expansion study investigating ALNUC in relapsed/refractory MM. Patients had ≥3 prior regimens, disease progression ≤60 days of last regimen, and were BCMA-directed therapy-naïve. ALNUC was administered intravenously (IV) and subcutaneously (SC); however, SC was selected for further evaluation due to the more favorable safety profile. Ninety-five patients received ALNUC SC; at data cutoff, 44.2% remained on treatment and median follow-up was 8.0 months. The recommended phase 2 dose was 30 mg. The most common treatment emergent adverse events (any grade/grade 3/4) were CRS (57.9%/0%), and neutropenia (53.7%/43.2%). Infections were also frequent (64.2%/14.7%). ORR was 58.9% for all ALNUC SC-treated patients and 71.4% for the 30-mg cohort; 47/95 (49.5%) were measurable residual disease (MRD) negative. Overall, the safety and efficacy of ALNUC SC were comparable to other BCMA-targeted therapies. These results support improved safety of SC versus IV, and corroborate a step-up dosing strategy to mitigate CRS. Importantly, a schedule that de-intensifies over time provides favorable toxicity that may be applicable to other bispecific engagers.

    2026Leukemia(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3Efficacy of Second-generation Transoral Incisionless Fundoplication (TIF 2.0) for Treatment of Gastroesophageal Reflux Disease (GERD) in Hill Grade (HG) III Gastroesophageal Junction (GEJ): A Systematic Review and Pooled Analysis
    Yinglin Gao,Fouad Jaber, Muaaz Masood, Ashwin Rao,Rajesh Krishnamoorthi, Charlie Borzy,John G. Hunter, J.M. Conchillo, Nicole B Bouvy,Bengt Håkanson,Lars Lundell,Ruben Hernaez,

    Transoral incisionless fundoplication (TIF) is FDA-approved for patients with hiatal hernia < 2 cm. The American Foregut Society (AFS) recommends TIF only for those with Hill Grade (HG) ≤ 2 and advises cruroplasty for HG ≥ 3, regardless of hernia size. However, many patients may decline or be unfit for surgery. We conducted a systematic review and individual patient data (IPD) pooled analysis to assess the efficacy of TIF 2.0 in patients with severe GERD and HG III anatomy. A systematic search of PubMed and EMBASE through May 2023 identified studies evaluating TIF 2.0. Studies involving cruroplasty (cTIF) or other endoscopic therapies were excluded. Authors of eligible studies were contacted to provide IPD for patients with HG III. The primary outcome was complete cessation of proton pump inhibitors (PPIs). Secondary outcomes included technical success, GERD metrics, HG classification post-TIF, adverse events, and need for reintervention. Twenty-three studies met inclusion criteria and 4 provided IPD for 28 patients with HG III anatomy. Mean age and BMI were 51.1 years and 26.5 kg/m², respectively. Technical success was 100

    2026Innovative Surgical Trends(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4From Static to Interactive: Authoring Interactive Visualizations Via Natural Language
    Can Liu, Jaeuk Lee, Tianhe Chen, Zhibang Jiang,Xiaolin Wen,Yong Wang

    Interactivity is crucial for effective data visualizations. However, it is often challenging to implement interactions for existing static visualizations, since the underlying code and data for existing static visualizations are often not available, and it also takes significant time and effort to enable interactions for them even if the original code and data are available. To fill this gap, we propose Athanor, a novel approach to transform existing static visualizations into interactive ones using multimodal large language models (MLLMs) and natural language instructions. Our approach introduces three key innovations: (1) an action-modification interaction design space that maps visualization interactions into user actions and corresponding adjustments, (2) a multi-agent requirement analyzer that translates natural language instructions into an actionable operational space, and (3) a visualization abstraction transformer that converts static visualizations into flexible and interactive representations regardless of their underlying implementation. Athanor allows users to effortlessly author interactions through natural language instructions, eliminating the need for programming. We conducted two case studies and in-depth interviews with target users to evaluate our approach. The results demonstrate the effectiveness and usability of our approach in allowing users to conveniently enable flexible interactions for static visualizations.

    20262026 IEEE 19th Pacific Visualization Conference (PacificVis)(2026)引用:1
    引用
    AI阅读
    加入学术空间
    5Asynchronous Contralateral Primaries of Small Cell Carcinoma of the Ovary, Hypercalcemic Type in Germline SMARCA4 Pathogenic Variant Carriers.
    Ben L Kong,Brett E Johnson, Julian Egger,Jayne M Stommel, Allison L Creason,Shawn Campbell,Adam J Krieg,Gordon B Mills, Tanja B Pejovic,Somayyeh Fahiminiya,W Glenn McCluggage, Afrida Ahmed,
    2026JCO precision oncology(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 942 篇论文

    合作机构(100)

    华盛顿大学合作论文 77
    德克萨斯大学奥斯汀分校合作论文 30
    科罗拉多州立大学合作论文 25
    斯坦福大学合作论文 22
    克利夫兰诊所合作论文 21
    加州大学合作论文 21
    俄勒冈健康与科学大学合作论文 20
    Cancer Clinic合作论文 20
    哥伦比亚大学合作论文 19
    西奈山伊坎医学院合作论文 19

    机构统计